The Reserve Bank of India is considering all of its available options to stabilize the rupee, including an interest rate hike, more currency swaps and raising dollars from investors overseas, according to people familiar with the matter. Top officials at the RBI, including Governor Sanjay Malhotra , have held a series of internal meetings to discuss the possible course of actions available after t...
The Reserve Bank of India is considering all of its available options to stabilize the rupee, including an interest rate hike, more currency swaps and raising dollars from investors overseas, according to people familiar with the matter. Top officials at the RBI, including Governor Sanjay Malhotra , have held a series of internal meetings to discuss the possible course of actions available after the rupee plunged to a fresh low of almost 97 to a dollar this week, the people said, asking not to be identified because the discussions are private. One of the options on the table is raising interest rates, one of the people said. The next scheduled monetary policy decision is on June 5, although the RBI has previously made an out-of-cycle adjustment in May 2022. Other measures include raising dollars overseas through a deposit scheme for non-resident Indians and selling a sovereign dollar bond, another person said. The latter would be decided by the government, the person said. The measures under consideration mirror some of those taken during the 2013 taper tantrum period. India provided a deposit scheme for non-residents through local banks at the time to spur foreign currency inflows. The RBI estimates the deposit schemes could draw as much as $50 billion this time around, according to one of the people, compared with about $30 billion previously. There is an increasing recognition among policymakers that the rupee is tumbling faster than anticipated, according to the people, who are familiar with the RBI’s thinking. Policymakers are of the opinion that India’s economic fundamentals remain strong and the banking system is sound, but that strength is not being reflected in the exchange rate, they said. The RBI didn’t respond to an email seeking further information. The top priority for the central bank now is to stop the depreciation, and the RBI is ready to do whatever it takes to achieve that, one of the people said. Raising borrowing costs would help spur foreign bo...
Key Points Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026. 10 stocks we like better than Viking Therapeutics › The introduction of GLP-1 weight-loss drugs by Novo Nordisk (NYSE: NVO) may have changed the pharmaceutical industry forever. Although there are...
Key Points Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026. 10 stocks we like better than Viking Therapeutics › The introduction of GLP-1 weight-loss drugs by Novo Nordisk (NYSE: NVO) may have changed the pharmaceutical industry forever. Although there are drawbacks to taking GLP-1 drugs (such as muscle loss), they are viewed as a miracle drug by many who have struggled for years with obesity. That said, which company is the best investment? Here are three different ways to play the space in 2026. Eli Lilly: Still the industry leader Novo Nordisk was first to market, but Eli Lilly's (NYSE: LLY) GLP-1 shot proved more effective. And when Novo Nordisk faced production issues, the decision to choose Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became even easier. The growth of Mounjaro and Zepbound has been nothing short of phenomenal, with Mounjaro's sales up 125% in the first quarter of 2026, and Zepbound up by 80%. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Eli Lilly recently introduced a GLP-1 pill, but it has a different active ingredient, and uptake has been a bit sluggish (more on this below). Still, the strength of Mounjaro and Zepbound remains impressive, and investors have taken notice. If you prefer to stick with industry leaders, Eli Lilly could be the right choice for your portfolio. The one problem is that the stock is expensive, with a price-to-earnings ratio of 35x, as earnings appear to be catching up to the stock's lofty price. Novo Nordisk: The underdog is making a comeback Novo Nordisk was the first to market with a GLP-1 shot, and it was the first to market with a GLP-1 pill. Notably, the drug company's pill contains ...
堅尼地城有單位冒煙起火 消防救出三隻狗 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】堅尼地城有單位冒煙起火,無人受傷。 起火單位不斷冒出濃煙,消防一度升起升降台射水,數十名居民自行疏散。下午約四時半,警方接獲數...
堅尼地城有單位冒煙起火 消防救出三隻狗 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】堅尼地城有單位冒煙起火,無人受傷。 起火單位不斷冒出濃煙,消防一度升起升降台射水,數十名居民自行疏散。下午約四時半,警方接獲數人報案,指加多近街恆裕大廈發生火警,消防動用一條喉及派出一隊煙帽隊撲救,在單位內救出三隻狗。火警在約二十分鐘後救熄,無人受傷,起火原因有待調查。